Synaptogenix (NASDAQ:SNPX) Announces Quarterly Earnings Results

Synaptogenix (NASDAQ:SNPX) announced its earnings results on Thursday. The company reported ($4.36) earnings per share (EPS) for the quarter, Zacks reports.

Synaptogenix Trading Up 1.1 %

NASDAQ:SNPX traded up $0.03 during trading hours on Thursday, reaching $2.67. 8,365 shares of the company were exchanged, compared to its average volume of 31,040. The business has a 50 day moving average of $2.97 and a 200 day moving average of $3.03. Synaptogenix has a 1-year low of $2.15 and a 1-year high of $6.22.

About Synaptogenix

Synaptogenix, Inc operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. The company focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. It also evaluates therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease.